Anaptysbio Stock Today
| ANAB Stock | USD 19.83 1.64 7.64% |
Performance0 of 100
| Odds Of DistressLess than 7
|
AnaptysBio is trading at 19.83 as of the 19th of April 2024, a -7.64 percent decrease since the beginning of the trading day. The stock's open price was 21.47. AnaptysBio has only a 7 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for AnaptysBio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2024 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of January 2017 | Category Healthcare | Classification Health Care |
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 26.76 M outstanding shares of which 4.3 M shares are presently shorted by private and institutional investors with about 11.43 trading days to cover. More on AnaptysBio
Moving together with AnaptysBio Stock
| 0.65 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against AnaptysBio Stock
| 0.6 | MRKR | Marker Therapeutics | PairCorr |
| 0.53 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
AnaptysBio Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. AnaptysBio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding AnaptysBio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Hamza Suria | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering AnaptysBio report their recommendations after researching AnaptysBio's financial statements, talking to executives and customers, or listening in on AnaptysBio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering AnaptysBio. The AnaptysBio consensus assessment is calculated by taking the average forecast from all of the analysts covering AnaptysBio. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the analysis of AnaptysBio's profitability, liquidity, and operating efficiency, AnaptysBio may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of AnaptysBio is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AnaptysBio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to AnaptysBio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AnaptysBio's financial leverage. It provides some insight into what part of AnaptysBio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AnaptysBio (ANAB) is traded on NASDAQ Exchange in USA. It is located in 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801 and employs 117 people. AnaptysBio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 530.71 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AnaptysBio's market, we take the total number of its shares issued and multiply it by AnaptysBio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. AnaptysBio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 26.76 M outstanding shares of which 4.3 M shares are presently shorted by private and institutional investors with about 11.43 trading days to cover.
AnaptysBio currently holds about 442.15 M in cash with (120.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66.
Check AnaptysBio Probability Of Bankruptcy
Ownership AllocationAnaptysBio retains a total of 26.76 Million outstanding shares. The majority of AnaptysBio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AnaptysBio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AnaptysBio. Please pay attention to any change in the institutional holdings of AnaptysBio as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check AnaptysBio Ownership Details
AnaptysBio Stock Price Odds Analysis
What are AnaptysBio's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of AnaptysBio jumping above the current price in 90 days from now is about 99.0%. The AnaptysBio probability density function shows the probability of AnaptysBio stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8708. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, AnaptysBio will likely underperform. Additionally, anaptysBio has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of AnaptysBio to move above the current price in 90 days from now is about 99.0 (This AnaptysBio probability density function shows the probability of AnaptysBio Stock to fall within a particular range of prices over 90 days) .
AnaptysBio Stock Institutional Holders
Institutional Holdings refers to the ownership stake in AnaptysBio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of AnaptysBio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing AnaptysBio's value.| Instituion | Recorded On | Shares | |
| Point72 Asset Management, L.p. | 2023-09-30 | 791.2 K | |
| Palo Alto Investors, Llc | 2023-12-31 | 686.9 K | |
| Saturn V Capital Management Llc | 2023-12-31 | 664.3 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 597.9 K | |
| Millennium Management Llc | 2023-09-30 | 446.2 K | |
| Eventide Asset Management, Llc | 2023-12-31 | 427 K | |
| Franklin Resources Inc | 2023-12-31 | 405.1 K | |
| Geode Capital Management, Llc | 2023-09-30 | 399.6 K | |
| 5am Venture Management, Llc | 2023-12-31 | 357.7 K | |
| Ecor1 Capital, Llc | 2023-09-30 | 7.5 M | |
| Deep Track Capital, Lp | 2023-12-31 | 2 M |
AnaptysBio Historical Income Statement
AnaptysBio Income Statement is one of the three primary financial statements used for reporting AnaptysBio's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of AnaptysBio revenue and expense. AnaptysBio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, AnaptysBio's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 19 M, whereas Operating Income is projected to grow to (156.2 M). View More FundamentalsAnaptysBio Stock Against Markets
Picking the right benchmark for AnaptysBio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in AnaptysBio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for AnaptysBio is critical whether you are bullish or bearish towards AnaptysBio at a given time. Please also check how AnaptysBio's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in AnaptysBio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
AnaptysBio Corporate Directors
AnaptysBio corporate directors refer to members of an AnaptysBio board of directors. The board of directors generally takes responsibility for the AnaptysBio's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of AnaptysBio's board members must vote for the resolution. The AnaptysBio board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Nicholas Lydon | Independent Director | Profile | |
| James Schoeneck | Independent Director | Profile | |
| John Schmid | Independent Director | Profile | |
| Ware | Independent Director | Profile |
How to buy AnaptysBio Stock?
Before investing in AnaptysBio, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in AnaptysBio. To buy AnaptysBio stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of AnaptysBio. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase AnaptysBio stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located AnaptysBio stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased AnaptysBio stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as AnaptysBio, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy AnaptysBio Stock please use our How to Invest in AnaptysBio guide.
Already Invested in AnaptysBio?
The danger of trading AnaptysBio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AnaptysBio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AnaptysBio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AnaptysBio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.Note that the AnaptysBio information on this page should be used as a complementary analysis to other AnaptysBio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is AnaptysBio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.08) | Revenue Per Share 0.637 | Quarterly Revenue Growth 0.323 | Return On Assets (0.18) | Return On Equity (0.93) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.